Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

1 września 2026 zaktualizowane przez: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Trial to Explore the Efficacy and Safety of Different Doses of TQC3927 Inhaled Powder in Patients With Chronic Obstructive Pulmonary Disease

This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic obstructive pulmonary disease, and to observe the symptoms and pharmacokinetic (PK) characteristics of participants.

Przegląd badań

Status

Zawieszony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

90

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Chiny
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chiny, 100144
        • Peking University Shougang Hospital
    • Guangxi
      • Yulin, Guangxi, Chiny, 537000
        • The First People' Hospital Of YuLin
    • Heilongjiang
      • Daqing, Heilongjiang, Chiny, 163000
        • Da Qing Long Nan Hospital
    • Henan
      • Anyang, Henan, Chiny, 455099
        • The People's Hospital of Anyang City
    • Hubei
      • Yichang, Hubei, Chiny, 443003
        • Yichang Central People's Hospital
    • Hunan
      • Xiangtan, Hunan, Chiny, 411200
        • Xiangtan County People's Hospital
    • Jiangsu
      • Yangzhou, Jiangsu, Chiny, 225000
        • Northern Jiangsu People's Hospital
      • Yixing, Jiangsu, Chiny, 214200
        • Yixing People's Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Chiny, 330000
        • Jiangxi Provincal People's Hospital
    • Jilin
      • Siping, Jilin, Chiny, 136099
        • Siping Central People's Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chiny, 200433
        • Shanghai Pulmonary Hospital
    • Shanxi
      • Linfen, Shanxi, Chiny, 041099
        • Linfen Central Hospital
    • Sichuan
      • Chengdu, Sichuan, Chiny, 610031
        • Chengdu Third People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chiny, 300140
        • The Fourth Central Hospital of Tianjin
    • Xinjiang
      • Ürümqi, Xinjiang, Chiny, 832008
        • The First Affiliated Hospital of Shihezi University Shihezi
    • Zhejiang
      • Wenzhou, Zhejiang, Chiny, 325027
        • The 2th School of Medicine ,WMU/The 2th affiliated Hospital and Yuying Children's Hospital of WMU

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Sign an informed consent form before the trial to fully understand the purpose, procedure, and possible adverse reactions;
  • Age: 40 years ≤ age ≤ 75 years (calculated from the date of signing the informed consent form), gender not limited;
  • Participants' body mass index (BMI) is within the range of 18~30 kg/m2 (including the borderline), and their weight is ≥45kg;
  • Diagnosed with Chronic Obstructive Lung Disease (COPD) according to the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and symptoms consistent with COPD for at least 1 year before the screening visit (V1);
  • Participants must have discontinued short-acting β2-adrenergic receptor agonist (SABA) for at least 6 hours and short-acting cholinergic receptor antagonist (SAMA) for at least 8 hours before starting any pulmonary function tests;
  • Participants must be current or former smokers with a smoking history of ≥10 pack-years (pack-year: number of packs per day × number of years of smoking, such as 1 pack of 20 cigarettes per day for 10 consecutive years, or 10 cigarettes per day for 20 consecutive years); former smokers are defined as those who have quit smoking for at least 6 months prior to Visit 1. Note: Use of pipes, cigars, and e-cigarettes cannot be used to calculate packs/year;
  • Trained participants are able to perform acceptable and reproducible pulmonary function tests according to American Thoracic Society/European Respiratory Society (ATS/ERS) 2005 criteria;
  • Participants voluntarily sign informed consent forms and have no plans for pregnancy within 90 days from the start of treatment to the last dose, and voluntarily use medically approved contraception (including with their partners);
  • Trained participants are able to correctly use a pressure metered-dose inhaler (pMDI), dry powder inhaler (DPI) inhaler for drug administration;
  • Participants are able to attend study visits on time and complete the visit content;

Exclusion Criteria:

  • Participants currently diagnosed with asthma (including asthma with COPD) or with a history of asthma, based on the investigator's judgment;
  • Participants with a current life-threatening COPD history;
  • Participants with concurrent active or clinically significant respiratory illnesses that significantly impact the study;
  • Participants with serious illnesses other than COPD, or abnormalities in laboratory tests, electrocardiograms, medical history, or physical examinations;
  • Participants who have undergone lung volume reduction surgery, lobectomy/segmentectomy, or are expected to undergo lung surgery during the study period within 12 months prior to V1;
  • Participants who have developed pneumonia or lower respiratory tract infections requiring antibiotic treatment within 8 weeks prior to V1 or between V1 and V3;
  • Participants with clinically significant abnormalities on chest computed tomography (CT);
  • Participants currently using positive pressure ventilation;
  • Participants requiring long-term oxygen therapy (oxygen therapy time > 15 minutes). 10. Individuals undergoing pulmonary rehabilitation;
  • Participants who changed their smoking status (i.e., started or stopped smoking) or began a smoking cessation program within 6 weeks prior to screening;
  • Individuals with unstable or life-threatening heart disease;
  • Individuals using non-selective oral beta-blockers;
  • Individuals with unstable or uncontrolled hypertension;
  • Abnormal values in clinically significant safety laboratory tests determined by the investigator at the screening visit;
  • Positive results for human immunodeficiency virus (HIV); positive results for hepatitis B surface antigen (HBsAg); positive results for hepatitis C virus (HCV) antibody and supporting documentation.
  • Individuals with a confirmed history of neurological or psychiatric disorders, including epilepsy or dementia requiring treatment;
  • Individuals with a history or current condition of neuropsychiatric, respiratory, cardiovascular, digestive, hematopoietic, lymphatic, immune, hepatic or renal insufficiency, endocrine, musculoskeletal, or other diseases;
  • Individuals who have participated in any drug or medical device clinical trial and received a study intervention within 4 weeks or 5 drug half-lives (whichever is longer) prior to screening;
  • Individuals who have lost or donated more than 400 ml of blood within 3 months prior to the trial. 21. Individuals with a known history of drug or food allergies, especially to components similar to the investigational drug;
  • Individuals who have frequently consumed alcohol within the 6 months prior to screening, or who have tested positive for alcohol in a breathalyzer test;
  • Individuals who have received a live attenuated vaccine within 28 days prior to randomization, an inactivated vaccine within 7 days prior to randomization, or are scheduled to receive a vaccine during the study period;
  • Individuals with a history of any organ or systemic malignancy within the past 5 years;
  • Individuals with a history of drug abuse within the past 2 years, or who have tested positive for drug abuse;
  • Individuals assessed by the investigators as unable to discontinue prohibited drugs as specified in the protocol during the screening and treatment phases of this study;
  • Pregnant or lactating women, or female participants with positive pregnancy test results;
  • Individuals with difficulty obtaining venous blood or a history of fainting from needles or blood loss;

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: 400 μg TQC3927 inhalation aerosol
The experimental group was given 400 μg of TQC3927 inhalation powder twice daily for a total of 14 days.
Lek: TQC3927 inhalation aerosol
TQC3927 inhaled powder: TQC3927 exhibits dual-target activity against anticholinergic antagonists and adrenergic receptor agonists (MABA).
Eksperymentalny: 600 μg TQC3927 inhalation aerosol
The experimental group was given 600 μg of TQC3927 inhalation powder twice daily for a total of 14 days.
Lek: TQC3927 inhalation aerosol
TQC3927 inhaled powder: TQC3927 exhibits dual-target activity against anticholinergic antagonists and adrenergic receptor agonists (MABA).
Aktywny komparator: glycopyrronium bromide and formoterol inhaled aerosol
The positive control group for glycopyrronium bromide formoterol inhalation aerosol (Baiwoping® Lingchang®) was given twice daily for 14 days.
Lek: Glyceryl bromide/formoterol inhalation aerosol
Glycerone bromide formoterol inhaler: long-acting adrenergic receptor agonists (LABA) + long-acting anticholinergic antagonists (LAMA) combination therapy.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The area under the FEV1 curve (AUC)
Ramy czasowe: Within 14 days
The area under the curve (AUC) of the change in FEV1 from baseline (ΔFEV1) 0-12 h after the first dose of Day 14.
Within 14 days

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
FEV1 peak
Ramy czasowe: Within 14 days
Changes in peak FEV1 from baseline after first administration on day 1, day 8, and day 14.
Within 14 days
FEV1 morning valley value
Ramy czasowe: Within 14 days
Changes from baseline in FEV1 morning trough values at Day 2, D8 before the first dose, and 12 hours after the second dose on Day 14 (Day 15).
Within 14 days
The area under the FVC curve (AUC)
Ramy czasowe: Within 14 days
The areas under the curve (AUC) of FEV1 and FVC changes from baseline (ΔFEV1 and ΔFVC) at 0-6 hour, 0-8 hour, and 0-12 hour after the first dose of D1; the areas under the curve (AUC) of FEV1 changes from baseline (ΔFEV1) and FVC changes from baseline (ΔFVC) at 0-6 hour, 0-8 hour, and 0-12 hour after the first dose of Day 14.
Within 14 days
FEV1
Ramy czasowe: Within 14 days
The change in FEV1 from baseline at each time point within 12 hours after the first dose on Day 1 and the first dose on Day 14.
Within 14 days
CAT rating
Ramy czasowe: Within 14 days
Changes from baseline in Patient Self-Assessment Test (CAT) scores for D8 and D14 chronic obstructive pulmonary disease.
Within 14 days
Scale for measuring dyspnea, cough, and sputum
Ramy czasowe: Within 14 days
Changes in the total score and individual item scores of the Dyspnea, Cough and Sputum Scale (BCSS) from baseline at each time point from Day 1 to Day 7, Day 8 to Day 14, and Day 1 to Day 14.
Within 14 days
Salbutamol Sulfate Inhalation Aerosol
Ramy czasowe: Within 14 days
Frequency and number of uses of the emergency medication salbutamol sulfate inhaler (Ventolin®) during a 2-week treatment period.
Within 14 days
Ctroμgh
Ramy czasowe: Within 14 days
Ctroμgh: Blood drug concentration at the end of the dosing interval (before the next dose); PK: The entire process of absorption, distribution, metabolism, and excretion in the body, and the pattern of blood drug concentration changes over time.
Within 14 days
Maximum mid-expiratory flow
Ramy czasowe: Within 14 days
Changes in maximum mid-expiratory flow (MMEF) from baseline at each time point after the first dose on day 1, day 8, and day 14.
Within 14 days
Adverse events (AEs)
Ramy czasowe: Within 7 weeks
Adverse events (AEs) refer to all adverse medical events that occur after a participant receives the investigational drug. These can manifest as symptoms, signs, illnesses, or abnormal laboratory tests, but are not necessarily causally related to the investigational drug.
Within 7 weeks

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2026

Ukończenie studiów (Szacowany)

1 stycznia 2027

Daty rejestracji na studia

Pierwszy przesłany

3 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

3 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

8 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

1 września 2026

Ostatnia weryfikacja

1 kwietnia 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • TQC3927-II-01

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj